成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

R-(+)-Lansoprazole

R-(+)-Lansoprazole Struktur
138530-94-6
CAS-Nr.
138530-94-6
Englisch Name:
R-(+)-Lansoprazole
Synonyma:
Dexlansoprazole;TAK 390;T 168390;D-lansoprazole;Dexlansaprazole;Dexlanzoprazole;T 168390,TAK 390;(+)-Lansoprazole;R-(+)-Lansoprazole;Lansoprazole R-Isomer
CBNumber:
CB71269821
Summenformel:
C16H14F3N3O2S
Molgewicht:
369.36
MOL-Datei:
138530-94-6.mol

R-(+)-Lansoprazole Eigenschaften

Schmelzpunkt:
66-68?C
Siedepunkt:
555.8±60.0 °C(Predicted)
Dichte
1.50±0.1 g/cm3(Predicted)
storage temp. 
Sealed in dry,2-8°C
L?slichkeit
Chloroform (Slightly), DMSO (Slightly), Methanol (Slightly)
Aggregatzustand
Solid
pka
9.56±0.10(Predicted)
Farbe
Off-White to Dark Brown
Stabilit?t:
Hygroscopic
Sicherheit
  • Risiko- und Sicherheitserkl?rung
  • Gefahreninformationscode (GHS)
Bildanzeige (GHS) GHS hazard pictogramsGHS hazard pictograms
Alarmwort Warnung
Gefahrenhinweise
Code Gefahrenhinweise Gefahrenklasse Abteilung Alarmwort Symbol P-Code
H317 Kann allergische Hautreaktionen verursachen. Sensibilisierung der Haut Kategorie 1A Warnung GHS hazard pictogramssrc="/GHS07.jpg" width="20" height="20" /> P261, P272, P280, P302+P352,P333+P313, P321, P363, P501
H373 Kann die Organe sch?digen bei l?ngerer oder wiederholter Exposition. Spezifische Zielorgan-Toxizit?t (wiederholte Exposition) Kategorie 2 Warnung P260, P314, P501
Sicherheit
P260 Dampf/Aerosol/Nebel nicht einatmen.
P261 Einatmen von Staub vermeiden.
P272 Kontaminierte Arbeitskleidung nicht au?erhalb des Arbeitsplatzes tragen.
P280 Schutzhandschuhe/Schutzkleidung/Augenschutz tragen.
P302+P352 BEI BERüHRUNG MIT DER HAUT: Mit viel Wasser/... (Hersteller kann, falls zweckm??ig, ein Reinigungsmittel angeben oder, wenn Wasser eindeutig ungeeignet ist, ein alternatives Mittel empfehlen) waschen.
P314 Bei Unwohlsein ?rztlichen Rat einholen / ?rztliche Hilfe hinzuziehen.
P321 Besondere Behandlung
P333+P313 Bei Hautreizung oder -ausschlag: ?rztlichen Rat einholen/?rztliche Hilfe hinzuziehen.
P363 Kontaminierte Kleidung vor erneutem Tragen waschen.
P501 Inhalt/Beh?lter ... (Entsorgungsvorschriften vom Hersteller anzugeben) zuführen.

R-(+)-Lansoprazole Chemische Eigenschaften,Einsatz,Produktion Methoden

Beschreibung

The mechanism of PPIs involves the irreversible binding to the hydrogen/potassium adenosine triphosphatase enzyme system, commonly referred to as the gastric proton pump, of the gastric parietal cell. As the last stage in gastric acid secretion, blockade of the gastric proton pump is an effective treatment for a variety of diseases requiring acid suppression, such as heartburn, peptic ulcers, and GERD. Dexlansoprazole is the latest PPI to hit the market, joining the ranks of omeprazole, rabeprazole, pantoprazole, esomeprazole, and lansoprazole, and is the Renantiomer of the racemic lansoprazole. Compared to its predecessors, dexlansoprazole exhibits improved pharmacokinetics with slower clearance and longer terminal half-life. In addition, dexlansoprazole utilizes a novel DDR technology; drug release is optimized through the use of granules with different pH-dependent dissolution profiles, thereby providing an initial release in the proximal small intestine within 1-2 h of administration followed by a subsequent release at distal regions of the small intestine several hours later. With its longer duration of action culminating in more effective acid suppression, dexlansoprazole may have an advantage over conventional PPIs that possess single release formulations (immediate or delayed). Similar to all PPIs, dexlansoprazole is a prodrug that consists of pyridine and benzimidazole rings with a latent sulfenamide moiety. In order to form the disulfide bond with cysteine residues of the proton pump, dexlansoprazole must be activated through two protonations followed by a spontaneous rearrangement to unmask the sulfenamide.

Chemische Eigenschaften

Brown Solid

Verwenden

The R-enantiomer of Lansoprazole; a gastric proton pump inhibitor. An antiulcerative

Clinical Use

Takeda Pharmaceuticals received approval of dexlansoprazole, a dual release formulation of the (R)-isomer of lansoprazol proton pump inhibitor (PPI) already in the market, from the FDA in January 2009. Dexlansoprazole is a delayed release capsule for the oncedaily, oral treatment of heartburn associated with symptomatic non-erosive gastroesophageal reflux disease (GERD), the healing of erosive esophagitis (EE) and the maintenance of healed EE. The dual release formulation is designed to provide two separate releases of medication, one at 1–2 h and then another at 4–5 h after treatment, for extended efficacy in the treatment of GERD.

Nebenwirkungen

The most commonly recorded adverse reactions that occurred at a higher incidence than placebo were diarrhea, abdominal pain, nausea, vomiting, flatulence, and upper respiratory tract infection. As dexlansoprazole inhibits gastric acid secretion, its use is expected to interfere with the absorption of drugs with pH-dependent oral bioavailability. Since the HIV protease inhibitor atazanavir is dependent on gastric acid for absorption, dexlansoprazole should not be co-administered with atazanavir to avoid a loss of therapeutic efficacy. While co-administration of dexlansoprazole did not affect the pharmacokinetics of warfarin or INR (international normalized ratio: the ratio of a patient s prothrombin time to a normal sample), there have been reports of increased INR and prothrombin time in patients receiving concomitant treatment with PPIs and warfarin. Since increases in INR and prothrombin time may lead to abnormal bleeding and possibly death, concomitant use of dexlansoprazole and warfarin may necessitate monitoring for increases in INR and prothrombin time.

R-(+)-Lansoprazole Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


R-(+)-Lansoprazole Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 309)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Henan Bao Enluo International TradeCo.,LTD
+86-17331933971 +86-17331933971
deasea125996@gmail.com China 2472 58
Henan Fengda Chemical Co., Ltd
+86-371-86557731 +86-13613820652
info@fdachem.com China 20288 58
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
+86-18600796368 +86-18600796368
sales@sjar-tech.com China 375 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21639 55
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32820 60
career henan chemical co
+86-0371-86658258 +8613203830695
sales@coreychem.com China 29886 58
Hubei Jusheng Technology Co.,Ltd.
18871490254
linda@hubeijusheng.com CHINA 28172 58
Casorganics US Corp
+17326109938
sales@casorganics.com CHINA 174 58
Standardpharm Co. Ltd.
86-714-3992388
overseasales1@yongstandards.com United States 14332 58
BOC Sciences
+1-631-485-4226
inquiry@bocsci.com United States 19553 58

138530-94-6()Verwandte Suche:


  • (R)-2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl]methyl]sulfinyl]-1H-benzimidazole
  • 1H-Benzimidazole, 2-[(R)-[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]- (9CI)
  • 1H-Benzimidazole, 2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-, (R)-
  • R-(+)-Lansoprazole
  • 2-[(R)-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
  • T 168390
  • TAK 390
  • 2-[[3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl]methylsulfinyl]-1H-benzoimidazole
  • 2-[(R)-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]sulfinyl]-
  • (+)2-[(R)-{[3-METHYL-4-(2,2,2-TRIFLUOROETHOXY) PYRIDIN-2-YL-1H-BENZIMIDAZOLE
  • T 168390,TAK 390
  • (R)-2-(((3-Methyl-4-(2,2,2-trifluoroethoxy)pyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole
  • Dexlansoprazole 22.5% enteric coated pellets
  • Lansoprazole R-Isomer
  • 1H-BenziMidazole,2-[(R)-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]Methyl]sulfinyl]-
  • Lansoprazole Impurity 14
  • Dexlansoprazole related impurities 2
  • Dexlansoprazole / R-(+)-Lansoprazole
  • Lansoprazole impurity 17/Lansoprazole R-Isomer/(R)-Lansoprazole/Dexlansoprazole/2-[(R)-[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
  • R-(+)-Lansoprazole USP/EP/BP
  • Dexlansaprazole
  • DexlansoprazoleQ: What is Dexlansoprazole Q: What is the CAS Number of Dexlansoprazole Q: What is the storage condition of Dexlansoprazole
  • Dexlansoprazole
  • Dexlanzoprazole
  • (+)-Lansoprazole
  • D-lansoprazole
  • Dexlansoprazole|||T 168390|||TAK 390|||R-(+)-Lansoprazole
  • 138530-94-6
  • DEXILANT
  • APIs
  • Chiral Reagents
  • Intermediates & Fine Chemicals
  • Pharmaceuticals
  • Sulfur & Selenium Compounds
Copyright 2019 ? ChemicalBook. All rights reserved